Wondering what’s being developed in the world of psoriasis treatment?
We reviewed articles from December 2023, to March 11th 2024, and broke it down for you here.
There were a lot of successful clinical trials showing new and innovative psoriasis treatments.
There was a new tool created to predict the development of psoriatic arthritis. Early detection can change lives.
Home phototherapy was evaluated to be as effective as in office. Meaning, if you wanted to, you could just buy a home phototherapy setup.
Biologics like abatacept and Otezla continued to show efficacy for treating psoriasis, while high-dose Skyrizi demonstrated potential for psoriasis remission.
These developments signify a changing landscape in psoriasis treatment, and lay a foundation for hopeful years ahead. If anything, the main takeaway is that scientific study on psoriasis is moving fast and we expect to see a lot more exciting news from the rest of 2024.
**Nov 29, 2023**
Analysis of Revolutionary Advances Unveil New Psoriasis Therapeutic Approaches
Researchers reviewed recent information on the biological mechanisms and new treatments for psoriasis.
This is worthy of being on the list because a methodical review brings recent information into perspective for future scientists.
Just like our review is trying to put development in perspective for you!
– [Link]
**Dec 7, 2023**
ALTB-268 Shows Promise for Psoriasis
AltruBio’s Phase 2 trial for ALTB-268 in ulcerative colitis hints at potential benefits for psoriasis treatment due to a unique mechanism of action.
Whenever a unique mechanism is mentioned it means scientists have imagined an entirely new way to deal with symptoms. This is always a good lead to follow! Hopefully it goes somewhere!
– [Link]
**Dec 13, 2023**
VTAMA Cream Improves Psoriasis in Small Trial
In a very small, first of its kind, trial, VTAMA cream was combined with biologics and demonstrated a notable 52% success rate in reducing psoriasis to 1% body surface area, offering a potentially powerful alternative therapy. This will require much further investigation but it shows that there may be a new way to treat psoriasis in combination with the two.
– [Link]
**Dec 18, 2023**
FDA Greenlights Can-Fite’s Pediatric Psoriasis Plan
Can-Fite received an FDA positive response for Piclidenoson in treating children with psoriasis, potentially addressing the treatment gap for pediatric patients.
– [Link]
**Jan 2, 2024**
TYK2 Inhibitors Advance for Psoriasis Treatment
Sudo Biosciences’ raised $116 million for study of TYK2 enzyme inhibitors. One of the inhibitors is a first in it’s class designed to treat skin diseases like psoriasis. These new treatments will be investigated for addressing psoriasis and multiple sclerosis, offering potential control over inflammation. This represents the development of cutting-edge drugs that have the potential to expand options and help more people with hard to treat psoriasis.
– [Link]
**Jan 17, 2024**
Arctic Bioscience Completes Volunteer Recruitment for HRO350 Trial
Arctic Bioscience’s Phase IIb trial for HRO350, a new oral drug for mild-to-moderate psoriasis, completes volunteer recruitment, signaling progress in addressing psoriasis patients’ needs.
One of the big hurdles in clinical research is recruitment, so really this is great news. Hopefully the results are good!
– [Link]
**Jan 23, 2024**
Tremfya Significantly Clears Scalp Psoriasis in Diverse Skin Tones
Tremfya (guselkumab) shows positive results in a phase 3 trial, significantly aiding in clearing moderate to severe scalp psoriasis across diverse skin tones.
Phase 3 trial success is a good thing, especially when it shows efficacy across different skin tones. If the phase 3 trials are still doing well it means that new options are coming to market.
– [Link]
New PRESTO Tool Predicts Psoriatic Arthritis Risk
The development of the PRESTO tool enables personalized risk prediction for psoriatic arthritis in individuals with psoriasis, aiding in early intervention and tailored treatment plans.
Early intervention can make a significant difference in the results of treatment, so this could be really good!
– [Link]
**Jan 24, 2024**
Study Reveals Mechanisms Behind Psoriatic Arthritis
Research led by Siba Raychaudhuri at UC Davis Health unveils how cytokines drive abnormal tissue accumulation in joints, offering insights into potential targeted therapies for psoriatic arthritis.
– [Link]
**Jan 29, 2024**
Bimzelx Shows Promise in Psoriatic Arthritis
UCB’s new drug Bimzelx provides hope for effective psoriatic arthritis treatment, particularly for patients unresponsive to other drugs.
New treatment options are always good. Even if they don’t pan out it’s just one more brick in the wall towards a solution.
– [Link]
**Feb 7, 2024**
JNJ-2113 Shows Positive Results in Phase 2b Study
Investigational targeted oral peptide JNJ-2113 demonstrates positive results in reducing moderate to severe plaque psoriasis symptoms, paving the way for further evaluation in Phase 3 trials.
– [Link]
**Feb 8, 2024**
FDA Approves Abatacept for Pediatric Psoriatic Arthritis
FDA approval of abatacept offers a safe and effective biologic treatment for children aged 2 and older with psoriatic arthritis, expanding options and improving outcomes for young patients.
– [Link]
**Feb 13, 2024**
Artax Initiates Phase 2a Trial for AX-158 in Psoriasis
Artax Biopharma begins Phase 2a trial to evaluate AX-158, a novel Nck blocker, potentially providing a safer and more effective treatment option for psoriasis by modulating the immune system.
– [Link]
**Feb 16th, 2024**
Somatic Mutations Not Direct Cause of Psoriasis
New research challenges the direct link between somatic mutations in skin cells and psoriasis, suggesting a more complex origin. The study opens avenues for exploring immune cells in understanding and treating psoriasis.
– [Link]
**Feb 27, 2024**
Spatial Transcriptomics Study Reveals Psoriasis Progression
Recent spatial transcriptomics research unveils immune cell distributions in psoriasis-affected skin, providing insights into disease severity and systemic implications for tailored treatment strategies.
– [Link]
**Mar 8, 2024**
SB17 Biosimilar Shows Comparable Outcomes to Stelara
A study presented at the AAD Annual Meeting indicates that SB17, a proposed biosimilar to Stelara, exhibits comparable outcomes to Stelara in treating moderate to severe plaque psoriasis, pending FDA approval.
– [Link]
Risankizumab Superior to Apremilast in Psoriasis Study
Risankizumab demonstrates superior efficacy over apremilast in improving quality of life and skin clearance in psoriasis patients with baseline scalp or nail involvement, according to the IMMpulse study.
– [Link]
**Mar 9, 2024**
JNJ-2113 Maintains Skin Clearance in Long-Term Study
Long-term study on JNJ-2113, an investigational oral peptide for plaque psoriasis, shows sustained efficacy and safety up to 52 weeks, indicating potential as an oral therapeutic option.
– [Link]
ESK-001 Phase 2 Trial Shows Positive Clinical Data
Alumis Inc. presents positive clinical data from a Phase 2 trial of ESK-001, a selective TYK2 inhibitor, offering hope for treating moderate-to-severe plaque psoriasis with Phase 3 trials planned for 2024.
– [Link]
Home Phototherapy Success for Psoriasis Treatment
A study spanning 2019 to 2023 demonstrates the effectiveness of home phototherapy for psoriasis, offering a convenient alternative to in-office treatment.
– [Link]
Amgen Presents New Data on Otezla at AAD 2024
Amgen unveils new Phase 3 study results for Otezla in children with plaque psoriasis and in palmoplantar pustulosis, showcasing sustained improvements and safety, promising new treatment options.
– [Link]
High Doses of Skyrizi Show Positive Psoriasis Remission
High doses of Skyrizi drive plaque psoriasis into remission and reduce resident memory T cells, hinting at a potential cure with early, aggressive treatment strategies, as presented by Dr. Andrew Blauvelt.
– [Link]
Concluding
Many new treatments are preforming well in their clinical trials for psoriasis. New studies into the causes of the disease are advancing medical knowledge, which will always result in better therapy down the line when new innovative options are proposed and then tested.
It’s safe to say that psoriasis treatment is active and progressing at a good pace!
